Oric Pharmaceuticals Inc
ORIC
NASDAQ
Biotechnology
$13.87
USD
+0.15 (+1.09%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.42B
Volume 828.5K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-140.35M
TTM
-2.3%
YoY
Operating Cash Flow
$-111.64M
TTM
+7.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 8.5 | 7.9 | 8.7 | 8.2 | 9.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 39.1 | 36.7 | 34.6 | 39.6 | 45.3 |
Operating Income | -39.1 | -36.7 | -34.6 | -39.6 | -45.3 |
EBITDA | -38.8 | -36.4 | -34.2 | -39.3 | -45.0 |
Other Income / Expense | 2.7 | 4.1 | 4.0 | 3.9 | 3.8 |
Total Other Income / Expense | 2.7 | 4.1 | 4.0 | 3.9 | 3.8 |
Income Before Income Taxes | -36.4 | -32.6 | -30.5 | -35.8 | -41.5 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -36.4 | -32.6 | -30.5 | -35.8 | -41.5 |
Consolidated Net Income / Loss | -36.4 | -32.6 | -30.5 | -35.8 | -41.5 |
Net Income Attributable to Common Shareholders | -36.4 | -32.6 | -30.5 | -35.8 | -41.5 |
Basic EPS | -$0.47 | -$0.33 | -$0.30 | -$0.34 | -$0.38 |
Diluted EPS | -$0.47 | -$0.33 | -$0.30 | -$0.34 | -$0.38 |
Basic Shares Outstanding | 78.1M | 99.0M | 103.1M | 105.5M | 108.0M |
Diluted Shares Outstanding | 78.1M | 99.0M | 103.1M | 105.5M | 108.0M |